A Study of Guselkumab in Participants With Active Lupus Nephritis

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Due to enrollment challenges, J\&J Innovative Medicine decided to stop screening and terminate the study early. This decision was not based on a safety concern.

Conditions

Lupus Nephritis

Interventions

DRUG: Guselkumab Dose 1
DRUG: Placebo
DRUG: Guselkumab Dose 2
DRUG: Standard-of-care treatment

Sponsor

Janssen Research & Development, LLC